EDSP: T IER 1 T ESTING I NFORMATION C OLLECTION ISRTP 2010 Endocrine Workshop EDSP Compliance December 13, 2010 Susan Ferenc, DVM, Ph.D.

Slides:



Advertisements
Similar presentations
Perspectives from EPA’s Endocrine Disruptor Screening Program
Advertisements

UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014
Medicaid Expansion in Pennsylvania Premium Assistance and the Medicaid Waiver Process.
Richard A. Becker, Ph.D., D.A.B.T American Chemistry Council Arlington, Virginia Comments on “Dose Setting” EDMVS Meeting July 23-24, 2002.
Brian A. Harris-Kojetin, Ph.D. Statistical and Science Policy
Washington Headquarters Services Executive Services Directorate Information Management Division OMB Collection Number Paperwork Reduction Act – DoD Public.
FDA Research: Clearance Requirements and Implications Steven L. Bradbard, Ph.D. Team Leader, Consumer Studies CFSAN/ORPSS.
From Cutting Red Tape to Maximizing Net Benefits Alexander T. Hunt U.S. Office of Management and Budget Challenges on Cutting Red Tape Rotterdam, The Netherlands.
1 High Production Volume (HPV) Challenge Program Diane Sheridan Chief, Existing Chemicals Branch, Chemical Control Division, Office of Pollution Prevention.
ISO 9001 : 2000.
Priority-setting for the Endocrine Disruptor Screening Program: Pesticide Active Ingredients Penelope A. Fenner-Crisp Office of Pesticide Programs U.S.
Endocrine Screening – Phase 1 TSCA 8(e) and FIFRA 6(a)(2) Requirements A. Michael Kaplan, Ph.D. December 13, 2010 A. Michael Kaplan & Associates, LLC
ISRTP 2009 Endocrine Workshop | 9-10 September 2009 | Washington, DC.
RTI International is a trade name of Research Triangle Institute The International Society of Regulatory Toxicology and Pharmacology (ISRTP)
EDSP Validation Gary E.Timm Senior Technical Advisor Office of Science Coordination and Policy U.S. Environmental Protection Agency.
Section 18 Final Rule Overview Presentation originally given by EPA at Emergency Exemption Process Revisions Workshop, revised by Laura Quakenbush.
NIH Research Contracts Richard L. Hartmann Chief, DMID Research Contracts Branch A National Institute of Allergy and Infectious Diseases.
Trini Torres-Carrion. AGENDA Overview of ED 524B Resources Q&A.
Employed Educator Report (EER) Report Form & Instructions.
Per Anders Eriksson
Research Methods for the Social Sciences: Ethics Ryan J. Martin, Ph.D. Thomas N. Cummings Research Fellow March 9, 2010.
Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.
What Information Fulfills EDSP Screening Requirements?
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
Quill Law Group LLC1 EDSP Implementation Business and Legal Considerations Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
Quill Law Group LLC1 EDSP Compliance EDSP Phase 2 Policies and Procedures Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
Status of the U.S. Endocrine Disruptor Screening Program (EDSP) Status of the U.S. Endocrine Disruptor Screening Program (EDSP) September
Verification. What is Verification? Verification is confirmation of eligibility for free and reduced price meals under NSLP and SBP. -Verification is.
N = By Number of Plans State Agencies with Approved SNAP-Ed Plans Approved Federal Funding Total = $379,088, ’s Funding.
Office of Pesticide Programs 21st Century Screening Assessment of Pesticides – A Regulatory View Vicki Dellarco, Ph.D. Senior Science Advisor Office of.
The Executive Office of the President (EOP). Office of Management and Budget (OMB)
The Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards The OMB SuperCircular Information for FTA Grantees.
EDSP’s Approach to Test Protocol Validation Office of Science Coordination and Policy U.S. Environmental Protection Agency.
Quill Law Group LLC1 Endocrine Disruption and Personal Care Products --- Legislative Developments Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington,
Quill Law Group LLC1 EDSP Compliance Timing, Procedural and Legal Issues Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
SBIR Budgeting Leanne Robey Chief, Special Reviews Branch, NIH.
Slide 1 of 24 EPA’s Endocrine Disruptor Screening Program (EDSP) Use of Exposure Data in Priority Setting Bill Wooge Office of Science Coordination and.
HFA Initiative Reporting Webinar June 30, Agenda Reporting Description Reporting Description –Overview/Rationale –Types of Reporting Upcoming Steps.
1 Tier 1 EDSP: Other Scientifically Relevant Information Barbara Neal Exponent December 13, 2010.
ELLEN MIHAICH, PH.D., DABT ENVIRONMENTAL AND REGULATORY RESOURCES ISRTP WORKSHOP DECEMBER 13, 2010 EDSP Test Guidelines and Guideline Modifications 1.
Slide 1 of 30 Endocrine Disruptor Screening Program (EDSP); Policies and Procedures for Initial Screening International Society of Regulatory Toxicology.
Wildlife Screens What Do They Tell Us? Dr. Pat Guiney Manager Global Safety, Regulatory & Environmental Assessment S.C. Johnson & Son, Inc. Racine, WI.
International Society of Regulatory Toxicology and Pharmacology 2009 Endocrine Workshop The Endocrine Disruptor Screening Program: What Can Screening Results.
CHEMSTEWARDS SOCMA COMPLIANCE MORE FOR MEMBERS - VISIT SIEF and Consortium Management Issues under REACH Dr. C. T. Helmes Senior Director.
Communications and the Endocrine Disruptor Screening Program ISRTP Workshop December 13, 2010.
Quill Law Group LLC1 EDSP Implementation Business and Legal Considerations Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
NOAA Cooperative Institutes John Cortinas, Ph.D. OAR Cooperative Institute Program, Program Manager NOAA Cooperative Institute Committee, Chairperson.
Christopher J. Borgert, PhD Weight of Evidence Determinations for EPA’s EDSP ISRTP Workshop, December 13 Lister Hill Auditorium, Bethesda, MD.
Introduction to Session II: Incorporating Existing Data into the EDSP Erik R. Janus Director, Human Health Policy CropLife America.
1 Geospatial Line of Business Update FGDC Coordination Group April 14, 2009.
American Recovery and Reinvestment Act of 2009 Energy Efficiency and Conservation Block Grant Program Small City and County Grant Kick-Off Meeting California.
STESEG taskforce on timeliness and benchmarkingJune The Short-term economic statistics: STES Timeliness Framework Richard McKenzie OECD.
EDSP Implementation: Concerns for the Pesticide Industry ISRTP 2009 Endocrine Workshop: The Endocrine Disruptor Screening Program: What Can Screening Results.
Temporary Assistance for Needy Families Part 265: Data Collection and Reporting.
What’s your friend up to? Subrecipient Monitoring Issues Tom Egan, MIT OSP Jeannette Gordon, Division of Grants Compliance and Oversight OPERA, OER, NIH.
Paediatric Medicine: The Paediatric Investigation Plan
Endocrine Disruptor Screening and Testing: An Industry Update
Basic Principles of Good Management
Annex III to BS/SC/PDF/A(2003)1
EIA approval process, Management plan and Monitoring
U.S. FDA Center for Devices and Radiological Health Update
CHANGE CONTROL.
Standards and Guidelines For Cognitive Interviews
Comments on Using Existing Data for the Endocrine Screening Testing Lorenz Rhomberg, PhD Principal Gradient ISRTP 2009 Endocrine Workshop.
U.S. Information Quality Standards
International Standards for Compilation of Statistics: The Gap between Standards Adoption and Standards Implementation Katherine K. Wallman Chief Statistician.
TLQAA STANDARDS & TOOLS
University of Pittsburgh
Section 3 FOR HUD USE ONLY.
Presentation transcript:

EDSP: T IER 1 T ESTING I NFORMATION C OLLECTION ISRTP 2010 Endocrine Workshop EDSP Compliance December 13, 2010 Susan Ferenc, DVM, Ph.D

Information Collection Request (ICR) Agencies requesting submission of information by the public must demonstrate the “practical utility,” or benefit, of the information and enumerate the public “burden,” or cost, of the collection – The Tier 1 data and OSRI are needed and will be used to provide information that will allow EPA to determine “that a chemical does, or is not likely to, have the potential to interact with the endocrine system.”

ICR Practical Utility: Means “the actual not merely theoretical or potential, usefulness of information to or for an agency, taking into account its accuracy, validity, adequacy, and reliability, and the agency’s ability to process the information it collects in a useful and timely fashion…” Burden: Means “the total time, effort or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency, including: Developing, acquiring, installing, and utilizing technology and systems for the purpose of collecting, validating, and verifying information; Searching data sources.”

EDSP Information Collection Request OMB Action: Approved with Change “Terms of Clearance” “…under the principles of the PRA, EPA should promote and encourage test order recipients to submit Other Scientifically Relevant Information (OSRI) in lieu of performing all or some of the Tier I assays, and EPA should accept OSRI as sufficient to satisfy the test orders to the greatest extent possible.” “…to further validate EPA’s burden estimates, OMB requests that EPA provide a report re-estimating the burden of this information collection based on responses to the Tier I test orders, including the use of cost-sharing and data compensation, the submission and acceptance of existing data and OSRI, and description of any instances in which submission of OSRI was deemed insufficient to satisfy the testing order.” “… in order to ensure that EPA has maximized the practical utility of the Tier I assays…, EPA should ensure sufficient opportunity prior to submission of any revision to this collection for public comment and peer review of the EPA tools to be developed to guide the agency decisions on whether a chemical must proceed to Tier II, including the Weight of Evidence Approach and Standard Evaluation Procedures.”

Status of List 1 Activity All responses to List 1 Test Orders have been submitted EPA has made OSRI decisions on 15 chemicals Of the 58 List 1 pesticide active ingredients: 30 are being “supported” in consortia 143 members in total, 4-5 members per consortia on average, range of 2-17 members 21 are being “supported” by a single company 7 are not being “supported” 20 registrations have been voluntarily cancelled Of the 9 List 1 pesticide inert ingredients: 2 inerts are being “supported” in consortia One consortium of 2 companies, the other of 7 (so far) Data Submission OSRI submitted for 46 actives New Data generated for 5 actives and 2 inerts 769 Test Orders sent out: 173 responses to “support,” 596 “other” responses (e.g., formulators exemption, opt-out of pesticide market, not subject to test order, response outstanding) There will be only one final response for each “supported” chemical

ASSAYSCodeAvg In Vitro Assays: Androgen Receptor Binding (Rat Prostate) $21,035 Aromatase (Human Recombinant) $10,060 Estrogen Receptor Binding (Rat Uterine) $21,035 ER Transcriptional Activation $15,113 Steroidogenisis (Human Cell Line) $16,222 In Vivo Assays: Fish Sort Term Reproduction $114,767 Hershberger (Rat) $30,190 Female Pubertal (Rat) $76,770 Male Pubertal (Rat) $77,740 Amphibian Metamorphosis (Frog) $106,087 Uterotrophic (Rat) $32,140 TOTAL$521,158

Total Cost of OSRI (46 chemicals)*$1,584,000 Per Chemical Submission$34,435 Per Test Order Recipient*$8,909 Estimated Costs for Generation and Submission of OSRI

ASSAYSCodeAvgOSRISavings In Vitro Assays: Androgen Receptor Binding $21,0352$42,070 Aromatase (Human Recombinant) $10,0600$0 Estrogen Receptor Binding $21,0352$42,070 ER Transcriptional Activation $15,1132$30,227 Steroidogenisis (Human Cell Line) $16,2220$0 In Vivo Assays: Fish Sort Term Reproduction $114,7670$0 Hershberger (Rat) $30,1904$120,760 Female Pubertal (Rat) $76,7702$153,540 Male Pubertal (Rat) $77,7404$310,960 Amphibian Metamorphosis (Frog) $106,0872$212,173 Uterotrophic (Rat) $32,1402$64,280 TOTAL$521,158$976,080

Total Burden EPACPDA List 1 Tier 1 Program$35,923,228$70,840,814 List 2 Tier 1 Program$52,071,780$121,906,952 Battery Costs for List 1$34,917,586 Battery Costs for List 2$69,835,172

Thank you!